|
|
|
|
Genentech announces topline results from Phase III trial of Avastin
XenaCare Holdings' Cobroxin to be available for purchase in WalgreensXenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer...EMEA grants Genta's request for SME designationGenta Incorporated announced that it has...
|
|
|
Genentech announces topline results from Phase III trial of Avastin
XenaCare Holdings' Cobroxin to be available for purchase in WalgreensXenaCare Holdings, Inc., a company specializing in the marketing and retail distribution of consumer...EMEA grants Genta's request for SME designationGenta Incorporated announced that it has...
|
|
|
US Seeks More Information About J&J Antipsychotic Marketing
The U.S.government has asked Johnson & Johnson (JNJ) for more information about the sales and marketing of the antipsychotics Risperdal and Invega, continuing a years-long probe. J&J disclosed in a regulatory filing Monday the...
|
|
|
US Seeks More Information About J&J Antipsychotic Marketing
The U.S.government has asked Johnson & Johnson (JNJ) for more information about the sales and marketing of the antipsychotics Risperdal and Invega, continuing a years-long probe. J&J disclosed in a regulatory filing Monday the...
|
|
|
US Seeks More Information About J&J Antipsychotic Marketing (DJ)
US Seeks More Information About J&J Antipsychotic Marketing By Peter Loftus Of DOW JONES NEWSWIRES The U.S.government has asked Johnson & Johnson (JNJ) for more information about the sales and marketing of the antipsychotics Risperdal and Invega,...
|
|
|
US Seeks More Information About J&J Antipsychotic Marketing (DJ)
US Seeks More Information About J&J Antipsychotic Marketing By Peter Loftus Of DOW JONES NEWSWIRES The U.S.government has asked Johnson & Johnson (JNJ) for more information about the sales and marketing of the antipsychotics Risperdal and Invega,...
|
|
|
US Seeks More Information About J&J Antipsychotic Marketing
By Peter Loftus Of DOW JONES NEWSWIRES The U.S.government has asked Johnson & Johnson (JNJ) for more information about the sales and marketing of the antipsychotics Risperdal and Invega, continuing a years-long probe. J&J disclosed in a...
|
|
|
Commercial Insight: Antipsychotics - Revenues Of Depots And New Agents Will Partially Offset Generic Erosion -
New report provides detailed analysis of the Healthcare and Medical market Published on February 17, 2010by Press Office(Companiesandmarkets.com and OfficialWire)LONDON, ENGLAND In 2008, seven major market sales of antipsychotics reached $18.2 billion.
|
|
|
Commercial Insight: Antipsychotics - Revenues Of Depots And New Agents Will Partially Offset Generic Erosion - New Market Report Published
In 2008, seven major market sales of antipsychotics reached $18.2 billion.Datamonitor forecasts the market value to peak in 2011 when it will then succumb to generic erosion, particularly in the US where incursion is the most rapid. However, the commercial...
|
|
|
Blockbuster in Hand, It's Time to Show a Profit
David Gardner called it.Hes up 1,334%! See what Davids recommending that you buy NEXT! Operating profits. Positive earnings before interest and taxes. The anti-GM. No matter what you call it, that's what Elan (NYSE: ELN) is predicting this year --...
|
|
|
Blockbuster in Hand, It's Time to Show a Profit
David Gardner called it.Hes up 1,334%! See what Davids recommending that you buy NEXT! Operating profits. Positive earnings before interest and taxes. The anti-GM. No matter what you call it, that's what Elan (NYSE: ELN) is predicting this year --...
|
